Background Poor adherence to oral HIV pre-exposure prophylaxis (PrEP) diminishes its
clinical and public health benefits. This study synthesises evidence regarding …

Introduction Oral pre-exposure prophylaxis (PrEP) is an effective strategy to reduce the risk
of HIV transmission in high risk individuals. However, the effectiveness of oral pre-exposure …

Injectable long‐acting cabotegravir (CAB LA) is effective and safe for pre‐exposure HIV
prophylaxis. It is recently approved for clinical use in those at high risk of contracting HIV …

Background: Daily pre-exposure prophylaxis and event-driven pre-exposure prophylaxis
(PrEP) are efficacious in reducing HIV transmission among men who have sex with men …

Human immunodeficiency virus (HIV) sexual transmission among men who have sex with
men (MSM) has increased markedly in Beijing, China in the past decade. Pre-exposure …

Objective Since the recent introduction of preexposure prophylaxis (PrEP), several studies
have reported a decrease in the use of condoms and a rise in STIs among users. This rise in …

The rich tradition of stigma theoretics in marketing and consumer research develops
understanding of consumer stigma management, mitigated via marketing-mediated …

Introduction Oral pre‐exposure prophylaxis (Pr EP) for HIV prevention has been proven to
significantly reduce new HIV infections yet scale‐up has been slow. As contexts continue to …

Summary Background Since October, 2017 (and until October, 2020), pre-exposure
prophylaxis (PrEP) has only been available in England, UK, through the PrEP Impact Trial …

Background Pre-exposure prophylaxis (PrEP) is an effective and cost-effective strategy for
HIV prevention. Spain carried out an implementation study in order to assess the feasibility …